ESOMEPRAZOLE MAGNESIUM capsule, delayed release pellets United States - English - NLM (National Library of Medicine)

esomeprazole magnesium capsule, delayed release pellets

ncs healthcare of ky, inc dba vangard labs - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or d

PMS-ESOMEPRAZOLE DR CAPSULE (DELAYED RELEASE) Canada - English - Health Canada

pms-esomeprazole dr capsule (delayed release)

pharmascience inc - esomeprazole (esomeprazole magnesium dihydrate) - capsule (delayed release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

PMS-ESOMEPRAZOLE DR CAPSULE (DELAYED RELEASE) Canada - English - Health Canada

pms-esomeprazole dr capsule (delayed release)

pharmascience inc - esomeprazole (esomeprazole magnesium dihydrate) - capsule (delayed release) - 40mg - esomeprazole (esomeprazole magnesium dihydrate) 40mg - proton-pump inhibitors

TEVA-ESOMEPRAZOLE TABLET (DELAYED-RELEASE) Canada - English - Health Canada

teva-esomeprazole tablet (delayed-release)

teva canada limited - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

TEVA-ESOMEPRAZOLE TABLET (DELAYED-RELEASE) Canada - English - Health Canada

teva-esomeprazole tablet (delayed-release)

teva canada limited - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium dihydrate) 40mg - proton-pump inhibitors

ESOMEPRAZOLE GENERICHEALTH esomeprazole (as magnesium) 20 mg enteric-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

esomeprazole generichealth esomeprazole (as magnesium) 20 mg enteric-coated tablet bottle

lupin australia pty limited - esomeprazole magnesium, quantity: 22.264 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: purified water; purified talc; lactose monohydrate; crospovidone; light magnesium oxide; macrogol 400; hyprolose; macrogol 6000; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); polysorbate 80; silicon dioxide; iron oxide red; pregelatinised maize starch; povidone; microcrystalline cellulose; hypromellose phthalate; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

ESOMEPRAZOLE GENERICHEALTH esomeprazole (as magnesium) 40 mg enteric-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

esomeprazole generichealth esomeprazole (as magnesium) 40 mg enteric-coated tablet bottle

lupin australia pty limited - esomeprazole magnesium, quantity: 44.528 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; hypromellose phthalate; pregelatinised maize starch; macrogol 6000; light magnesium oxide; purified water; povidone; glyceryl monostearate; silicon dioxide; microcrystalline cellulose; crospovidone; macrogol 400; purified talc; iron oxide red; lactose monohydrate; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

ESOMEPRAZOLE TABLET (DELAYED-RELEASE) Canada - English - Health Canada

esomeprazole tablet (delayed-release)

ethypharm inc - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium dihydrate) 20mg - proton-pump inhibitors

ESOMEPRAZOLE TABLET (DELAYED-RELEASE) Canada - English - Health Canada

esomeprazole tablet (delayed-release)

ethypharm inc - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium dihydrate) 40mg - proton-pump inhibitors

ESOMEPRAZOLE TABLET (DELAYED-RELEASE) Canada - English - Health Canada

esomeprazole tablet (delayed-release)

sanis health inc - esomeprazole (esomeprazole magnesium dihydrate) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium dihydrate) 40mg - proton-pump inhibitors